We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| CervoMed Inc | NASDAQ:CRVO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.34 | -2.37% | 14.03 | 13.10 | 15.00 | 16.3071 | 13.93 | 15.75 | 41,547 | 01:00:00 |
From Jun 2024 to Jul 2024
Presentation Details Format: Corporate presentation Date: Thursday, July 18, 2024Time: 1:10 PM ETWebcast Link: click here
The webcast of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMedCervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
Investor Contact: PJ KelleherLifeSci AdvisorsInvestors@cervomed.com617-430-7579
1 Year CervoMed Chart |
1 Month CervoMed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
